NO306563B1 - Fremgangsmåte for fremstilling av et nytt t-PA-derivat, dettes DNA-sekvens og ekspresjonsplasmid - Google Patents
Fremgangsmåte for fremstilling av et nytt t-PA-derivat, dettes DNA-sekvens og ekspresjonsplasmid Download PDFInfo
- Publication number
- NO306563B1 NO306563B1 NO904211A NO904211A NO306563B1 NO 306563 B1 NO306563 B1 NO 306563B1 NO 904211 A NO904211 A NO 904211A NO 904211 A NO904211 A NO 904211A NO 306563 B1 NO306563 B1 NO 306563B1
- Authority
- NO
- Norway
- Prior art keywords
- plasmid
- derivative
- dna sequence
- mmol
- protein
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims description 20
- 239000013613 expression plasmid Substances 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 108
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 108
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 71
- 239000013612 plasmid Substances 0.000 claims description 40
- 241000588724 Escherichia coli Species 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 12
- 238000004153 renaturation Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000010828 elution Methods 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 7
- 210000003000 inclusion body Anatomy 0.000 claims description 6
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 5
- 108010053070 Glutathione Disulfide Proteins 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 claims description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Natural products OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 2
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000011097 chromatography purification Methods 0.000 claims 3
- 208000007536 Thrombosis Diseases 0.000 abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 102000035122 glycosylated proteins Human genes 0.000 abstract 1
- 108091005608 glycosylated proteins Proteins 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 28
- 230000002537 thrombolytic effect Effects 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000010410 reperfusion Effects 0.000 description 14
- 102000009123 Fibrin Human genes 0.000 description 13
- 108010073385 Fibrin Proteins 0.000 description 13
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 13
- 229950003499 fibrin Drugs 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 102000008946 Fibrinogen Human genes 0.000 description 12
- 108010049003 Fibrinogen Proteins 0.000 description 12
- 229940012952 fibrinogen Drugs 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 239000004475 Arginine Substances 0.000 description 10
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 235000009697 arginine Nutrition 0.000 description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
- 208000034158 bleeding Diseases 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 10
- 108010043984 Erythrina caffra trypsin inhibitor Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000013566 Plasminogen Human genes 0.000 description 5
- 108010051456 Plasminogen Proteins 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 3
- 108091027305 Heteroduplex Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 208000002528 coronary thrombosis Diseases 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000006167 equilibration buffer Substances 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 229960004198 guanidine Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010023237 Jugular vein thrombosis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000010405 reoxidation reaction Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 101001009976 Cerrena unicolor Laccase-2 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 244000266805 Lychnis coronaria Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 101000777480 Phyllodiscus semoni DELTA-alicitoxin-Pse1b Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- -1 pH 7.5 (6.5 mmol/1) Chemical compound 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 208000022064 reactive hyperemia Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Luminescent Compositions (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3903581A DE3903581A1 (de) | 1989-02-07 | 1989-02-07 | Gewebs-plasminogenaktivator-derivat |
PCT/EP1990/000194 WO1990009437A1 (de) | 1989-02-07 | 1990-02-06 | Gewebs-plasminogenaktivator-derivat |
Publications (3)
Publication Number | Publication Date |
---|---|
NO904211D0 NO904211D0 (no) | 1990-09-27 |
NO904211L NO904211L (no) | 1990-09-27 |
NO306563B1 true NO306563B1 (no) | 1999-11-22 |
Family
ID=6373566
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO904211A NO306563B1 (no) | 1989-02-07 | 1990-09-27 | Fremgangsmåte for fremstilling av et nytt t-PA-derivat, dettes DNA-sekvens og ekspresjonsplasmid |
NO2000002C NO2000002I1 (no) | 1989-02-07 | 2000-05-19 | Reteplase |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2000002C NO2000002I1 (no) | 1989-02-07 | 2000-05-19 | Reteplase |
Country Status (29)
Country | Link |
---|---|
US (1) | US5223256A (ko) |
EP (1) | EP0382174B1 (ko) |
JP (1) | JP2559538B2 (ko) |
KR (1) | KR970008485B1 (ko) |
AT (1) | ATE126270T1 (ko) |
AU (1) | AU623228B2 (ko) |
CA (1) | CA2025900C (ko) |
CZ (1) | CZ281836B6 (ko) |
DD (1) | DD291779A5 (ko) |
DE (2) | DE3903581A1 (ko) |
DK (1) | DK0382174T3 (ko) |
ES (1) | ES2031804T3 (ko) |
FI (1) | FI100244B (ko) |
GR (2) | GR900300140T1 (ko) |
HK (1) | HK153396A (ko) |
HU (1) | HU218092B (ko) |
IE (1) | IE61077B1 (ko) |
IL (1) | IL93280A (ko) |
LU (1) | LU90025I2 (ko) |
LV (1) | LV10302B (ko) |
NL (1) | NL970008I2 (ko) |
NO (2) | NO306563B1 (ko) |
NZ (1) | NZ232337A (ko) |
PT (1) | PT93082B (ko) |
RU (1) | RU2107094C1 (ko) |
SK (1) | SK279029B6 (ko) |
UA (1) | UA27111A1 (ko) |
WO (1) | WO1990009437A1 (ko) |
ZA (1) | ZA90861B (ko) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634007A (en) * | 1985-12-02 | 1987-01-06 | Adolph Coors Company | Carton blank with perforated tear line |
US5676947A (en) * | 1989-02-07 | 1997-10-14 | Boehringer Manneheim Gmbh | Method for treating thromboembolic conditions using thrombolytically active proteins |
DE3923339A1 (de) * | 1989-05-31 | 1990-12-06 | Boehringer Mannheim Gmbh | Gewebs-plasminogen-aktivator-derivat |
GB9019120D0 (en) * | 1990-09-01 | 1990-10-17 | Beecham Group Plc | Novel compounds |
DE4037196A1 (de) * | 1990-11-22 | 1992-05-27 | Boehringer Mannheim Gmbh | Verfahren zur reaktivierung von denaturiertem protein |
DE4123845A1 (de) * | 1991-07-18 | 1993-01-21 | Boehringer Mannheim Gmbh | Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe |
ES2082465T3 (es) * | 1991-04-16 | 1996-03-16 | Boehringer Mannheim Gmbh | Unidad farmaceutica de envasado que contiene activadores de plasminogeno para la administracion multiple de bolos. |
US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
DE4423574A1 (de) * | 1994-07-05 | 1996-01-11 | Boehringer Mannheim Gmbh | Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko |
AU4259496A (en) * | 1994-12-06 | 1996-06-26 | Boehringer Mannheim Gmbh | Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases |
US5723122A (en) * | 1995-06-01 | 1998-03-03 | Boehringer Mannheim Gmbh | Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases |
AU2660397A (en) * | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
US6083715A (en) * | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
TR200000172T2 (tr) * | 1997-07-23 | 2000-12-21 | Roche Diagnostics Gmbh | Mutasyona uğramış insan proteinlerinin insan hücrelerinde homolog tekrar birleşim ile üretilmesi. |
WO1999009185A1 (de) * | 1997-08-13 | 1999-02-25 | Roche Diagnostics Gmbh | Plasminogenaktivator mit verbesserter zymogenität |
WO1999009184A1 (de) * | 1997-08-13 | 1999-02-25 | Roche Diagnostics Gmbh | Plasminogenaktivator mit verbesserter zymogenität und verminderter fibrinbindung |
DE10105912A1 (de) * | 2001-02-09 | 2002-08-14 | Roche Diagnostics Gmbh | Rekombinante Proteinase K |
DE10153601A1 (de) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
AR068914A1 (es) * | 2007-10-18 | 2009-12-16 | Paion Deutschland Gmbh | Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia |
EP2289542A1 (en) | 2009-08-31 | 2011-03-02 | PAION Deutschland GmbH | Treatment of neurological or neurodegenerative disorders |
EP2289541A1 (en) | 2009-08-31 | 2011-03-02 | PAION Deutschland GmbH | Treatment of neurological or neurodegenerative disorders |
SG11201906530TA (en) | 2017-02-03 | 2019-08-27 | Acticor Biotech | Inhibition of platelet aggregation using anti-human gpvi antibodies |
JP2020520386A (ja) | 2017-05-16 | 2020-07-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 急性虚血性脳卒中の処置のための方法及び医薬組成物 |
WO2019238933A1 (en) | 2018-06-15 | 2019-12-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity |
WO2021148439A1 (en) | 2020-01-21 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stimulating cerebrovascular function |
US20240207190A1 (en) | 2020-06-09 | 2024-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fucoidan-functionalized polysaccharide particles with t-pa for targeted thrombolytic therapy |
WO2023156683A1 (en) | 2022-02-21 | 2023-08-24 | Acticor Biotech | Treatment of cardiovascular diseases using anti-human gpvi antibodies |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766075A (en) * | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
EP0112122B1 (en) * | 1982-12-14 | 1991-08-28 | South African Inventions Development Corporation | Plasminogen activator |
US4511502A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4620948A (en) * | 1982-12-22 | 1986-11-04 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4753879A (en) * | 1984-08-27 | 1988-06-28 | Biogen N.V. | Modified tissue plasminogen activators |
US5073494A (en) * | 1985-04-22 | 1991-12-17 | Genentech, Inc. | Human tissue plasminogen activator substituted at position 275 or at positions 275 and 277 |
JPH0672105B2 (ja) * | 1985-10-02 | 1994-09-14 | 持田製薬株式会社 | 血栓溶解剤及びその製法 |
DE3537708A1 (de) * | 1985-10-23 | 1987-04-23 | Boehringer Mannheim Gmbh | Verfahren zur aktivierung von t-pa nach expression in prokaryonten |
US4777043A (en) * | 1985-12-17 | 1988-10-11 | Genentech, Inc. | Stabilized human tissue plasminogen activator compositions |
US5034225A (en) * | 1985-12-17 | 1991-07-23 | Genentech Inc. | Stabilized human tissue plasminogen activator compositions |
DE3611817A1 (de) * | 1986-04-08 | 1987-10-15 | Boehringer Mannheim Gmbh | Verfahren zur renaturierung von proteinen |
DE3643158A1 (de) * | 1986-04-21 | 1987-11-19 | Boehringer Mannheim Gmbh | Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung |
US4898825A (en) * | 1986-05-07 | 1990-02-06 | Mitsui Toatsu Chemicals, Incorporated | Methods for purification of single-chain and double-chain tissue plasminogen activator |
JPH0779692B2 (ja) * | 1986-05-07 | 1995-08-30 | 三井東圧化学株式会社 | 一本鎖t−PAと二本鎖t−PAを分離する方法 |
JPS6463378A (en) * | 1986-08-11 | 1989-03-09 | Mitsui Toatsu Chemicals | Separation of single stranded tpa and double standard tpa |
SE8702562L (sv) * | 1987-06-18 | 1988-12-19 | Kabigen Ab | Nya fibrinolytiska enzymer |
US4935237A (en) * | 1988-03-21 | 1990-06-19 | Genentech, Inc. | Processes for the preparation of t-PA mutants |
IL87276A (en) * | 1987-08-03 | 1995-07-31 | Fujisawa Pharmaceutical Co | Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it |
US4963357A (en) * | 1987-10-09 | 1990-10-16 | Monsanto Company | Tissue plasminogen activator modified by the substitution of Arg for Cys at position 73, methods and pharmaceutical compositions therefor |
US5037752A (en) * | 1987-10-09 | 1991-08-06 | Monsanto Company | Modified tissue plasminogen activator substituted at cysteine-73 and lysine-277 |
-
1989
- 1989-02-07 DE DE3903581A patent/DE3903581A1/de not_active Withdrawn
-
1990
- 1990-01-30 IE IE34390A patent/IE61077B1/en not_active IP Right Cessation
- 1990-02-01 NZ NZ232337A patent/NZ232337A/xx unknown
- 1990-02-02 DD DD90337557A patent/DD291779A5/de not_active IP Right Cessation
- 1990-02-05 IL IL9328090A patent/IL93280A/en not_active IP Right Cessation
- 1990-02-06 UA UA4831496A patent/UA27111A1/uk unknown
- 1990-02-06 CZ CS90558A patent/CZ281836B6/cs not_active IP Right Cessation
- 1990-02-06 DE DE59009487T patent/DE59009487D1/de not_active Expired - Lifetime
- 1990-02-06 RU SU4831496A patent/RU2107094C1/ru active
- 1990-02-06 US US07/585,129 patent/US5223256A/en not_active Expired - Lifetime
- 1990-02-06 JP JP2502957A patent/JP2559538B2/ja not_active Expired - Lifetime
- 1990-02-06 KR KR1019900702203A patent/KR970008485B1/ko not_active IP Right Cessation
- 1990-02-06 ZA ZA90861A patent/ZA90861B/xx unknown
- 1990-02-06 HU HU644/90A patent/HU218092B/hu unknown
- 1990-02-06 EP EP90102329A patent/EP0382174B1/de not_active Expired - Lifetime
- 1990-02-06 CA CA002025900A patent/CA2025900C/en not_active Expired - Lifetime
- 1990-02-06 AU AU50470/90A patent/AU623228B2/en not_active Expired
- 1990-02-06 AT AT90102329T patent/ATE126270T1/de active
- 1990-02-06 DK DK90102329.1T patent/DK0382174T3/da active
- 1990-02-06 SK SK558-90A patent/SK279029B6/sk not_active IP Right Cessation
- 1990-02-06 WO PCT/EP1990/000194 patent/WO1990009437A1/de active IP Right Grant
- 1990-02-06 LU LU90025C patent/LU90025I2/fr unknown
- 1990-02-06 ES ES90102329T patent/ES2031804T3/es not_active Expired - Lifetime
- 1990-02-07 PT PT93082A patent/PT93082B/pt not_active IP Right Cessation
- 1990-09-27 NO NO904211A patent/NO306563B1/no not_active IP Right Cessation
- 1990-10-08 FI FI904951A patent/FI100244B/fi active IP Right Grant
-
1991
- 1991-09-27 GR GR90300140T patent/GR900300140T1/el unknown
-
1993
- 1993-06-01 LV LVP-93-448A patent/LV10302B/xx unknown
-
1995
- 1995-08-10 GR GR950402065T patent/GR3017099T3/el unknown
-
1996
- 1996-08-08 HK HK153396A patent/HK153396A/xx not_active IP Right Cessation
-
1997
- 1997-02-17 NL NL970008C patent/NL970008I2/nl unknown
-
2000
- 2000-05-19 NO NO2000002C patent/NO2000002I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO306563B1 (no) | Fremgangsmåte for fremstilling av et nytt t-PA-derivat, dettes DNA-sekvens og ekspresjonsplasmid | |
JP2631645B2 (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
IE861055L (en) | Plasminogen activator | |
JPH0448440B2 (ko) | ||
JPH0134596B2 (ko) | ||
Orsini et al. | Efficient renaturation and fibrinolytic properties of prourokinase and a deletion mutant expressed in Escherichia coli as inclusion bodies | |
RU2143490C1 (ru) | Бифункциональный вариант урокиназы, плазмида, содержащая синтетический структурный ген, кодирующий бифункциональную урокиназу, плазмида (варианты), способ получения плазмиды, способ получения бифункционального варианта урокиназы, тромболитическое средство | |
AU620927B2 (en) | A preparation of plasminogen activator expressed in prokaryotes | |
JPS6248378A (ja) | 新規な組織プラスミノーゲン活性化因子誘導体 | |
JP3329340B2 (ja) | トロンビン活性化プラスミノーゲン誘導体 | |
CA2017636C (en) | Derivative of tissue-type plasminogen activator | |
HUT52558A (en) | Process for production of derivatives of prouroquinase with small molecule mass and medical compositions containing them as active substance | |
US5723122A (en) | Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases | |
EP0796323A1 (en) | Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired | ||
CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA |
|
MK1K | Patent expired |